

GF/B45/EDP13 **Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Burkina Faso, Côte d'Ivoire and Rwanda)**

Approved on 5 August 2021

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER10; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses

Table 1: Secretariat's Recommendation on Funding from C19RM¹

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country/ Multicountry	Grant name	Currency	C19RM 2020 carry-over amount ²	Previously approved C19RM 2021 award ³	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
Burkina Faso	BFA-M-PADS	EUR	3,170,700	0	48,375,147	48,375,147	24.0%	51,545,847	11,435,261
Côte d'Ivoire	CIV-C-ACI	EUR	589,579	0	5,155,591	49,946,651	21.6%	53,599,092	8,812,733
	CIV-H-MOH	EUR	0	0	426,651				
	CIV-M-MOH	EUR	1,514,767	0	643,427				
	CIV-M-SCI	EUR	1,548,095	0	5,915,327				
	CIV-S-MOH	EUR	0	0	35,894,735				
	CIV-T-MOH	EUR	0	0	1,910,919				
Rwanda	RWA-C-MOH	US\$	8,449,550	11,329,802	36,210,536	47,540,337	25.0%	55,989,887	7,995,201

¹ The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

² Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

³ This includes Secretariat approved Fast-track and Full Funding awards, as well as awards previously approved by the Board.